Red-blood-cell volume as an index of alcoholism

Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

Blood·1999

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

Journal of the National Cancer Institute·1998

Progress with interferon in CML--results of the MRC UK CML III study.

Bone marrow transplantation·1996

Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.

Blood·1996

Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.

British journal of haematology·1995

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.

Lancet (London, England)·1995

Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study.

Lancet (London, England)·2026

Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial.

Lancet (London, England)·2026

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Lancet (London, England)·2026

Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment.

Journal of Alzheimer's disease : JAD·2026

A rare, spontaneous external jugular vein pseudoaneurysm: case report and literature review.

Frontiers in surgery·2026

Recurrent Hyperammonemic Encephalopathy in Adults with Citrin Deficiency: A Case Report of Two Genetically Confirmed Cases.

Journal of clinical medicine·2026

Room-Temperature Aqueous Synthesis of Amino-Functionalized Al-Based MOF as a Ratiometric Fluorescent Probe for Aqueous Dichromate Detection.

Molecules (Basel, Switzerland)·2026

Comparative Phytochemical Profiling and Biological Activities of Two Asplenium ceterach L. Extracts.

Molecules (Basel, Switzerland)·2026

Special Issue "Flow Cytometry: Applications and Challenges".

International journal of molecular sciences·2026

Related Experiment Videos

Red-blood-cell volume as an index of alcoholism

Related Concept Videos

Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

Progress with interferon in CML--results of the MRC UK CML III study.

Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.

Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.

Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study.

Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial.

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment.

A rare, spontaneous external jugular vein pseudoaneurysm: case report and literature review.

Recurrent Hyperammonemic Encephalopathy in Adults with Citrin Deficiency: A Case Report of Two Genetically Confirmed Cases.

Room-Temperature Aqueous Synthesis of Amino-Functionalized Al-Based MOF as a Ratiometric Fluorescent Probe for Aqueous Dichromate Detection.

Comparative Phytochemical Profiling and Biological Activities of Two Asplenium ceterach L. Extracts.

Special Issue "Flow Cytometry: Applications and Challenges".

Related Experiment Videos

Red-blood-cell volume as an index of alcoholism

Related Concept Videos

Related Articles